Seminars in Oncology
Volume 30, Issue 5 , Pages 667-676 , October 2003

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen

  • Neil H Bander

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Neil H. Bander, MD, The New York Presbyterian Hospital-Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • David M Nanus

      Affiliations

    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Matthew I Milowsky

      Affiliations

    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Lale Kostakoglu

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Shankar Vallabahajosula

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Stanley J Goldsmith

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA

References 

  1. Allen TM. Ligand, targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750–763
  2. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–936
  3. Israeli RS, Powell CT, Fair WR, et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1994;53:227–230
  4. Israeli RS, Powell CT, Fair WR, et al.  Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–1811
  5. Wright GL, Haley C, Beckett ML, et al.  Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol. 1995;1:18–28
  6. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552–558
  7. Sokoloff RL, Norton KC, Gasior CL, et al.  A dual-monoclonal sandwich assay for prostate-specific membrane antigen (Levels in tissues, seminal fluid and urine). Prostate. 2000;43:150–157
  8. Bostwick DG, Pacelli A, Blute M, et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma (A study of 184 cases). Cancer. 1998;82:2256–2261
  9. Wright GLJ, Grob BM, Haley C, et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–334
  10. Sweat SD, Pacelli A, Murphy GP, et al.  PSMA expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–640
  11. Pinto JT, Suffoletto B, Berzin TM, et al.  Prostate-specific membrane antigen (A novel folate hydrolase in human prostatic carcinoma cells). Clin Cancer Res. 1996;2:1445–1451
  12. Kahn D, Williams RD, Manyak MJ  The ProstaScint Study Group . 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 1998;159:2041–2046
  13. Kahn D, Williams RD, Haseman MK, et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284–289
  14. Yao D, Trabulsi EJ, Kostakoglu L, et al.  The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002;20:211–218
  15. Troyer JK, Feng Q, Beckett ML, et al.  Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol. 1995;1:29–37
  16. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232–242
  17. Liu H, Moy P, Kim S, et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–3634
  18. Liu H, Rajasekaran AK, Moy P, et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055–4060
  19. McDevitt MR, Barendswaard E, Ma D, et al.  An alpha-particle emitting antibody for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–6100
  20. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237–5243
  21. Rawlings ND, Barrett AJ. Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta. 1997;1339:247–252
  22. Smith-Jones PM, Vallabhajosula S, Navarro V, et al.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen (Preclinical studies in nude mice bearing LNCaP human prostate tumor). J Nucl Med. 2003;44:610–617
  23. Adams GP, Schier R, McCall AM, et al: High affinity restricts the localization of tumor penetration of single-chain fv antibody molecules. Cancer Res 62:4750–4755
  24. Hamilton A, King S, Liu H, et al.  A novel humanised antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res. 1998;39:440; (abstr)
  25. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev. 1978;5:199–207
  26. Bander NH, Nanus D, Bremer S, et al.  Clinical trial targeting a monoclonal antibody to the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer. Proc Am Soc Clin Oncol. 2000;19:477A; (abstr)
  27. Bander NH, Nanus D, Goldsmith SJ, et al.  Phase I trial of humanized monoclonal antibody to prostate specific membrane antigen/extracellular domain. Proc Am Soc Clin Oncol. 2001;20:181a; (abstr)
  28. Bander NH, Trabulsi EJ, Kostakoglu L, et al: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (in press)
  29. Chang SS, Reuter VE, Heston WDW, et al.  Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198
  30. Gong MC, Chang SS, Sadelain M, et al.  Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metast Rev. 1999;18:483–490
  31. Milowsky MI, Rosmarin AS, Cobham MV, et al.  Anti-PSMA mAb HuJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol. 2002;21:29; (abstr)

☆ Supported in part by NIH General Clinical Research Centers Program (NCRR Grant No. M01RR00047); US Department of Army (DAMD17-98-1-8594), Cancer Research Institute, Cap Cure, the David H. Koch Foundation, the Peter Sacerdote Foundation, BZL Biologics, Inc, and Millennium Pharmaceuticals, Inc. N.H.B. developed the J591 antibody used in this study. J591 and related anti-PSMAext antibody patents were assigned to the Cornell Research Foundation and subsequently licensed to BZL Biologics, Inc. N.H.B. is a paid consultant to BZL Biologics, Inc.

PII: S0093-7754(03)00358-0

doi: 10.1016/S0093-7754(03)00358-0

Seminars in Oncology
Volume 30, Issue 5 , Pages 667-676 , October 2003

Article Tools

* Image Usage & Resolution